Holen Sie sich die Stockscreener-App
19.28
1.15%
0.22
Handel nachbörslich:
19.99
0.71
+3.68%
Schlusskurs vom Vortag:
$19.06
Offen:
$18.78
24-Stunden-Volumen:
106.83K
Relative Volume:
0.48
Marktkapitalisierung:
$302.49M
Einnahmen:
$116.88M
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-137.71
EPS:
-0.14
Netto-Cashflow:
$-20.74M
1W Leistung:
+14.42%
1M Leistung:
+1.96%
6M Leistung:
+36.16%
1J Leistung:
+75.27%
1-Tages-Spanne:
$18.34
$19.49
1-Wochen-Bereich:
$16.43
$19.49
52-Wochen-Spanne:
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Firmenname
Rigel Pharmaceuticals
Sektor
Branche
Telefon
650-624-1100
Adresse
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RIGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
19.28 | 302.49M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-03 | Fortgesetzt | Piper Sandler | Neutral |
| 2022-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-08 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Eingeleitet | B. Riley Securities | Neutral |
| 2020-11-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Fortgesetzt | JP Morgan | Overweight |
| 2019-03-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Eingeleitet | Citigroup | Buy |
| 2018-05-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-31 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Bestätigt | Piper Jaffray | Overweight |
| 2016-07-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Bestätigt | Stifel | Buy |
| 2012-11-29 | Eingeleitet | UBS | Neutral |
| 2012-11-06 | Bestätigt | Oppenheimer | Outperform |
| 2012-03-26 | Eingeleitet | Canaccord Genuity | Hold |
| 2010-12-10 | Herabstufung | MP Advisors | Outperform → Market Perform |
Alle ansehen
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
Press Release Distribution & PR Platform - ACCESS Newswire
(RIGL) Trading Report - news.stocktradersdaily.com
Rigel (RIGL) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Stocks That Fell to 3-Year Lows in the Week of Sept. 13 - GuruFocus
Where are the Opportunities in (RIGL) - news.stocktradersdaily.com
Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability (RIGL) - Seeking Alpha
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
High Growth Tech Stocks in the US for April 2025 - simplywall.st
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26% - simplywall.st
Rigel settles patent litigation regarding its immune thrombocytopenia treatment - MSN
Rigel settles patent litigation over TAVALISSE treatment By Investing.com - Investing.com South Africa
Rigel Pharma stock rises on patent settlement (RIGL:NASDAQ) - Seeking Alpha
Rigel, Hetero Settle Patent Suit Over Platelet-Booster Tavalisse - Bloomberg Law News
Rigel climbs on blood disorder drug patent settlement - TradingView
Rigel settles patent litigation regarding its immune thrombocytopenia treatment (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma - Nasdaq
Rigel Pharmaceuticals Settles Patent Litigation Over Tavalisse - MarketScreener
Rigel Pharmaceuticals resolves patent litigation related to Tavalisse - TipRanks
Rigel Announces Settlement Agreement Resolving TAVALISSE® (Fostamatinib Disodium Hexahydrate) Patent Litigation - Marketscreener.com
Rigel settles patent litigation over TAVALISSE treatment - Investing.com
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation - PR Newswire
(RIGL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Bristol-Myers Squibb expands immuno-oncology pipeline with Flexus Biosciences, Rigel Pharmaceuticals deals - FirstWord Pharma
Rigel Pharmaceuticals appoints Mark W. Frohlich to board of directors - MSN
Statutory Profit Doesn't Reflect How Good Rigel Pharmaceuticals' (NASDAQ:RIGL) Earnings Are - Yahoo Finance
(RIGL) Investment Analysis and Advice - news.stocktradersdaily.com
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook - Investing.com India
Rigel Pharmaceuticals’ SWOT analysis: pipeline potential drives stock outlook By Investing.com - Investing.com South Africa
Rigel Looks Interesting, But Let's Wait For A Lower Price (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals appoints new board member By Investing.com - Investing.com Australia
Rigel Pharmaceuticals adds oncology expert to board By Investing.com - Investing.com Australia
SEC Form 4 filed by Director Frohlich Mark W - Quantisnow
Rigel Pharmaceuticals appoints new board member - Investing.com
Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update - Quantisnow
Rigel Pharmaceuticals Appoints Dr. Frohlich to Board - TipRanks
Rigel appoints Mark W. Frohlich to its board -March 10, 2025 at 12:01 pm EDT - Marketscreener.com
Rigel Pharmaceuticals adds oncology expert to board - Investing.com India
Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors - StockTitan
Rhumbline Advisers Has $423,000 Stock Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
FY2025 EPS Estimates for RIGL Increased by Cantor Fitzgerald - Defense World
Citigroup Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World
Rigel Pharmaceuticals Implements 1-for-10 Reverse Stock Split: Balancing Nasdaq Compliance and Investor Appeal - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded by StockNews.com to “Buy” - Defense World
What is B. Riley’s Forecast for RIGL Q1 Earnings? - Defense World
What is HC Wainwright’s Estimate for RIGL Q1 Earnings? - Defense World
Earnings call transcript: Rigel Pharmaceuticals Q4 2024 sees strong growth By Investing.com - Investing.com Australia
Rigel Pharmaceuticals, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next - Yahoo Finance
Rigel Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
B. Riley Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock - Defense World
HC Wainwright Reiterates Buy Rating for Rigel Pharmaceuticals (NASDAQ:RIGL) - Defense World
Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rigel Pharmaceuticals-Aktie (RIGL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schorno Dean L | EVP & Chief Financial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,734 |
38,020 |
57,235 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 04 '25 |
Sale |
20.92 |
2,125 |
44,457 |
53,500 |
| Santos David A | EVP, Chief Commercial Officer |
Feb 05 '25 |
Sale |
21.93 |
1,796 |
39,379 |
51,704 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 04 '25 |
Sale |
20.92 |
4,952 |
103,601 |
243,854 |
| RODRIGUEZ RAUL R | CEO, President |
Feb 05 '25 |
Sale |
21.93 |
4,400 |
96,474 |
239,454 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 04 '25 |
Sale |
20.92 |
1,448 |
30,294 |
40,169 |
| Furey Raymond J. | EVP, GC, CCO & Corp Sec |
Feb 05 '25 |
Sale |
21.93 |
1,339 |
29,359 |
38,830 |
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):